

# Patient selection rather than detection alone: Defining the surgical value of radioguided surgery in neuroendocrine tumors

Rıza Deryol

Department of Surgical Oncology, Ministry of Health, Istanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey

---

## ARTICLE INFO

---

*Article type:*

*Letter to the editor*

---

*Article history:*

Received: 6 Jun 2026

Revised: 14 Jun 2026

Accepted: 14 Jun 2026

---

## Dear Editor

We read with great interest the article by Uña-Gorospe et al., "Utility of radioguided surgery in the intraoperative localization of neuroendocrine tumors: Report of 3 cases," recently published in the *Asia Oceania Journal of Nuclear Medicine and Biology* (1). The authors should be congratulated for presenting a clinically relevant application of radioguided surgery in neuroendocrine tumors (NETs), particularly in cases where intraoperative gamma probe guidance enabled the identification of lesions that were indeterminate, faintly visualized, or not easily detectable by conventional imaging or direct surgical inspection.

This report highlights the technical feasibility of somatostatin receptor-based radioguided localization. However, we believe that its practical surgical value would be further strengthened by a clearer discussion on patient selection. In daily surgical oncology practice, the key question is not only whether radioguided surgery can detect additional NET lesions, but also in which patients this detection meaningfully changes the operative plan. This distinction is important because NET surgery is highly heterogeneous, ranging from limited local excision to formal oncologic resection with lymphadenectomy or tumor debulking.

Therefore, the incremental value of radioguided surgery may be greatest in selected

patients with suspected occult disease, equivocal preoperative functional imaging, small subserosal or nodal lesions, recurrent disease, or anatomically challenging locations where visual and tactile feedback is limited (2, 3).

A related point is the need to link intraoperative radiotracer findings to surgical endpoints. Reporting whether gamma probe findings altered the extent of resection, lymph node dissection, margin assessment, or confirmation of tumor bed clearance would make the technique more interpretable for surgeons. This is particularly relevant because complete macroscopic disease control and margin-oriented resection remain central principles in the management of resectable gastrointestinal NETs (3, 4). Without this operative correlation, radioguided surgery may be perceived primarily as a detection tool rather than a decision-changing adjunct.

Overall, we congratulate the authors for demonstrating the potential role of radioguided surgery in NET localization. Clarifying the patient selection criteria and the impact of intraoperative decisions would further enhance the practical value of this article for both nuclear medicine physicians and surgical oncologists.

## References

1. Uña-Gorospe JA, Romero-Acevedo S, Mora-Martín L. Utility of radioguided surgery in

---

\* *Corresponding author:* Rıza Deryol. Department of Surgical Oncology, Ministry of Health, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. G-434 Street No: 2L, Başakşehir Neighborhood, Başakşehir, Istanbul, Turkey. Tel: +90 212 909 60 00 / +90 506 563 3802; E-mail: dr.deryol@gmail.com

© 2026 *mums.ac.ir* All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

- the intraoperative localization of neuroendocrine tumors: Report of 3 cases. *Asia Oceania Journal of Nuclear Medicine and Biology*. 2026; 14(1): 112.
2. García-Talavera P, Ruano R, Rioja ME, Cordero JM, Razola P, Vidal-Sicart S. Radioguided surgery in neuroendocrine tumors. A review of the literature. *Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)*. 2014; 33(6): 358-65.
  3. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American Neuroendocrine Tumor Society. *Pancreas*. 2017; 46(6): 715-31.
  4. Panzuto F, Ramage J, Pritchard DM, Van Velthuysen ML, Schrader J, Begum N, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. *Journal of Neuroendocrinology*. 2023; 35(8): e13306.